Catalyst Dossier · compiled by CeliA 🧫

vTv Therapeutics Inc. (VTVT)

Pharmaceutical Preparations · market cap $22M · as of 2026-07-18

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-11

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

vTv Therapeutics (VTVT) is a small-cap clinical-stage pharmaceutical company with 23 employees and a ~$22M market cap, built around cadisegliatin (800 mg QD), a Phase 3 asset targeting Type 1 Diabetes Mellitus. The company carries $98.1M in net cash against a lean cost structure, with a high-impact Phase 3 readout for cadisegliatin estimated around September 15, 2026, representing the defining near-term binary event.

The catalyst path

2026-08-11Earningsimp 5/10
2027-04-15 (est.)Phase 3 · Cadisegliatin 800 mg QDimp 9/10

Pipeline

Asset	Phase	Indication
TTP054	Phase 2	Type 2 Diabetes Mellitus
TTP399 400 mg	Phase 2	Diabetes Mellitus, Type 2
GK1-399 (formerly TTP399)	Phase 2	Type 2 Diabetes Mellitus
Cadisegliatin 800 mg QD	Phase 3	Diabetes Mellitus, Type 1
TTP889	Phase 2	Venous Thromboembolism
TTP399	Phase 2	Diabetes Mellitus, Type 1
TTP273	Phase 2	Type 2 Diabetes Mellitus
TTP435	Phase 2	Obesity

Price & technical context

3-month

+2.2%

6-month

-8.5%

12-month

+116.7%

52-wk range

$14.00–$42.72

vs 50-day MA

-2.8%

vs 200-day MA

-2.8%

Realized vol

74.2%

Max drawdown

-46.9%

Daily closes through 2026-08-03. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for VTVT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.